- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05904080
Nivolumab- en ipilimumab-immunotherapie testen met of zonder het beoogde geneesmiddel Cabozantinib bij recidiverende, gemetastaseerde of ongeneeslijke neus-keelholtekanker
Gerandomiseerde fase 2-studie van nivolumab en ipilimumab met of zonder cabozantinib bij patiënten met gevorderd nasofarynxcarcinoom die progressie hebben vertoond na platinabehandeling en immunotherapie
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To determine if the progression-free survival (PFS) of the triplet combination (cabozantinib S-malate, nivolumab, and ipilimumab [CaboNivoIpi]) is more favorable than the doublet (nivolumab and ipilimumab [NivoIpi]).
SECONDARY OBJECTIVES:
I. To compare safety and tolerability between the two arms (Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0.).
II. To compare overall response rate (ORR) between the two arms via both Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST) criteria.
III. To compare overall survival (OS) between the two arms. IV. To assess response by primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy.
EXPLORATORY OBJECTIVE:
I. To evaluate molecular and immunologic predictors of response (Epstein-Barr virus [EBV] viral load; PD-L1 score) between arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.
ARM B: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate orally (PO) daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8-12 weeks until progression of disease occurs or a new non-protocol anti-cancer therapy is initiated and then every 6 months for up to 2 years.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
California
-
Irvine, California, Verenigde Staten, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Los Angeles, California, Verenigde Staten, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Verenigde Staten, 90020
- Keck Medicine of USC Koreatown
-
Los Angeles, California, Verenigde Staten, 90033
- Los Angeles General Medical Center
-
Newport Beach, California, Verenigde Staten, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
Orange, California, Verenigde Staten, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Verenigde Staten, 94304
- Stanford Cancer Institute Palo Alto
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30308
- Emory University Hospital Midtown
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Verenigde Staten, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Verenigde Staten, 83814
- Kootenai Health - Coeur d'Alene
-
Nampa, Idaho, Verenigde Staten, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Post Falls, Idaho, Verenigde Staten, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Verenigde Staten, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
Chicago, Illinois, Verenigde Staten, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Verenigde Staten, 60612
- University of Illinois
-
Danville, Illinois, Verenigde Staten, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Verenigde Staten, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Effingham, Illinois, Verenigde Staten, 62401
- Carle Physician Group-Effingham
-
Evanston, Illinois, Verenigde Staten, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva, Illinois, Verenigde Staten, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Verenigde Staten, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Glenview, Illinois, Verenigde Staten, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Verenigde Staten, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Verenigde Staten, 60426
- Ingalls Memorial Hospital
-
Highland Park, Illinois, Verenigde Staten, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Lake Forest, Illinois, Verenigde Staten, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Verenigde Staten, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Verenigde Staten, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
Orland Park, Illinois, Verenigde Staten, 60462
- University of Chicago Medicine-Orland Park
-
Orland Park, Illinois, Verenigde Staten, 60462
- Northwestern Medicine Orland Park
-
Urbana, Illinois, Verenigde Staten, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Verenigde Staten, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Iowa
-
Ankeny, Iowa, Verenigde Staten, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Verenigde Staten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Verenigde Staten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Verenigde Staten, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Verenigde Staten, 51503
- Methodist Jennie Edmundson Hospital
-
Council Bluffs, Iowa, Verenigde Staten, 51503
- Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
-
Des Moines, Iowa, Verenigde Staten, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Verenigde Staten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Verenigde Staten, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Verenigde Staten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Verenigde Staten, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02111
- Tufts Medical Center
-
-
Minnesota
-
Bemidji, Minnesota, Verenigde Staten, 56601
- Sanford Joe Lueken Cancer Center
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Verenigde Staten, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Verenigde Staten, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Verenigde Staten, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Verenigde Staten, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Verenigde Staten, 59901
- Logan Health Medical Center
-
Missoula, Montana, Verenigde Staten, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Verenigde Staten, 68114
- Oncology Associates PC
-
Omaha, Nebraska, Verenigde Staten, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
-
New Jersey
-
Basking Ridge, New Jersey, Verenigde Staten, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Verenigde Staten, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Verenigde Staten, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack, New York, Verenigde Staten, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Verenigde Staten, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Verenigde Staten, 11553
- Memorial Sloan Kettering Nassau
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Novant Health Presbyterian Medical Center
-
Huntersville, North Carolina, Verenigde Staten, 28078
- Novant Health Cancer Institute - Huntersville
-
Matthews, North Carolina, Verenigde Staten, 28105
- Novant Health Cancer Institute - Matthews
-
Mooresville, North Carolina, Verenigde Staten, 28117
- Novant Health Cancer Institute - Mooresville
-
-
North Dakota
-
Bismarck, North Dakota, Verenigde Staten, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Verenigde Staten, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Verenigde Staten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45220
- Good Samaritan Hospital - Cincinnati
-
-
Oklahoma
-
Lawton, Oklahoma, Verenigde Staten, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Verenigde Staten, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Ontario, Oregon, Verenigde Staten, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health and Science University
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Medical University of South Carolina
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Verenigde Staten, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Verenigde Staten, 23298
- VCU Massey Comprehensive Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, Verenigde Staten, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Verenigde Staten, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Verenigde Staten, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Verenigde Staten, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Verenigde Staten, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Verenigde Staten, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Verenigde Staten, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Verenigde Staten, 54476
- Marshfield Medical Center - Weston
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patients must have histologically documented nasopharyngeal carcinoma (NPC) regardless of World Health Organization (WHO) classification (keratinizing squamous cell carcinoma, non-keratinizing, or basaloid squamous cell carcinoma) and regardless of association with Epstein-Barr virus (EBV) and/or human papillomavirus (HPV)
-
Recurrent, metastatic and incurable disease treated with platinum-gemcitabine and prior PD-1/L1 blockade (as first or second-line therapy)
-
Patients are eligible regardless of prior smoking history, p16 immunohistochemistry (IHC) status, PD-L1 expression status, EBV tumor status, EBV viral load at baseline, or tumor genomic alteration status
-
Patients must have at least one measurable lesion (by RECIST v1.1) which has not been previously irradiated that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions as >= 10 mm (>= 1 cm) (and short axis for nodal lesions, LN >= 15 mm) with CT scan, MRI, or calipers by clinical exam
-
Patients may have had no more than 2 prior lines of prior systemic therapy for recurrent, metastatic NPC
-
No prior VEGFR targeted therapy permitted
-
Age >= 18 years
-
Eastern Cooperative Oncology Group Performance (ECOG) performance status 0-2
-
Absolute neutrophil count (ANC) >= 1,000/mm^3
-
Hemoglobin >= 9 g/dL
-
Platelet count >= 100,000/mm^3
-
Creatinine or creatinine clearance =< 1.5 mg/dL or >= 30 Modification of Diet in Renal Disease (MDRD)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN); except subjects with Gilbert syndrome who can have a total bilirubin < 3 mg/dL
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGT]) =< 3 x upper limit of normal (ULN)
- Up to =< 5 allowed with liver metastases
-
Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test, per institution standard, done =< 7 days prior to registration is required.
- Pregnant women are excluded from this study because nivolumab, ipilimumab, and cabozantinib are all Class C or D agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants, secondary to treatment of the mother with any of the study agents, breastfeeding should be discontinued if the mother is treated with as part of this study (in either arm)
-
No active tumor bleeding: or radiographic evidence of major blood vessel infiltration as judged by the treating investigator
-
Prior -anti-cancer therapy is allowed: Patients need to be recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), with the exception of alopecia. Any life-threatening events clearly attributable to prior immunotherapy exposure that have a high possibility of recurring should warrant exclusion: including severe pneumonitis, grade 4 bullous dermatitis/drug reaction with eosinophilia and systemic symptoms (DRESS), neurologic events such as autoimmune encephalitis transverse myelitis, and/or myocarditis. Maintenance hormonal replacement or long-term hormonal therapy exposure is permitted.
-
No chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration. Palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:
- Repeat imaging demonstrates no new sites of bone metastases.
- The lesion being considered for palliative radiation is not a target lesion
-
-
No patients with a prior malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
-
Brain metastases allowed: Patients with treated brain metastases are eligible if follow-up brain imaging 3 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
-
For patients with evidence of chronic hepatitis B (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently receiving treatment, they are eligible if they have an undetectable HCV viral load
-
Solid organ or tissue transplant is allowed: - subsequent therapy with nivolumab increases the risk of organ/tissue rejection. Patients must be instructed that it is crucial they stay in touch with their transplant team during treatment
-
No active autoimmune disease: or history of autoimmune disease that might recur, and which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include but are not limited to patients with a history of
- Immune related neurologic disease,
- Multiple sclerosis,
- Autoimmune (demyelinating) neuropathy,
- Guillain-Barre syndrome (GBS),
- Myasthenia gravis;
- Systemic autoimmune disease such as SLE,
- Connective tissue diseases,
- Scleroderma, inflammatory bowel disease (IBD),
- Crohn's, ulcerative colitis,
- Patients with a history of toxic epidermal necrolysis (TEN),
- Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease
-
Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible
-
Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome, and psoriasis controlled with topical medication and patients with only positive serology, such as antinuclear antibodies (ANA) or anti-thyroid antibodies, should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
Pneumonitis should be evaluated for the nature of the disease process, need for treatment prior study treatment, and the risk of exacerbation with study treatment
-
Able to swallow oral medication: No known medical condition causing an inability to swallow oral formulations of agents
-
No condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study registration. Patients are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
-
Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel) is prohibited. Allowed anticoagulants are the following:
- Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).
- Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
-
Concomitant use of any medications or substances that are strong inhibitors or inducers of CYP3A4 is discouraged; if unavoidable, the dose of cabozantinib on study should be adjusted accordingly. Any complementary medications (e.g., herbal supplements or traditional Chinese medicines) intended to treat the disease under study are prohibited
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm A (nivolumab, ipilimumab)
Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and collection of blood samples throughout the trial. |
Given IV
Andere namen:
Undergo MRI
Andere namen:
Given IV
Andere namen:
Undergo collection of blood samples
Andere namen:
Undergo CT scan
Andere namen:
|
|
Experimenteel: Arm B (nivolumab, ipilimumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial. |
Given IV
Andere namen:
Undergo MRI
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Undergo collection of blood samples
Andere namen:
Undergo CT scan
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival (PFS)
Tijdsspanne: From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years
|
PFS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall survival (OS)
Tijdsspanne: From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years
|
OS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years
|
|
Incidence of adverse events
Tijdsspanne: Up to 2 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the chi-square or Fisher's exact test. |
Up to 2 years
|
|
Response by subgroups of interest
Tijdsspanne: Up to 2 years
|
Will also report and compare the overall response rate (ORR) between different subgroups of interest (primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy (further defined below), etc.). These comparisons will be done via chi-square or Fisher's exact tests. We'll also assess primary versus acquired resistance to prior PD-1 inhibition in each arm as well. While not a formal stratification, in the interim and final analysis we'll also descriptively assess these subgroups between arms as well. |
Up to 2 years
|
|
ORR
Tijdsspanne: Up to 2 years
|
The response rate will be compared via chi-square or Fisher's exact tests between the 2 treatment arms using both the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and also separately for the immune-modified RECIST criteria. |
Up to 2 years
|
|
Predictors of response
Tijdsspanne: Up to 2 years
|
Will correlate the baseline data (Epstein-Barr virus viral load, p16 immunohistochemistry status, smoking history, and PD-L1 score) with ORR data. For this analysis, logistic regression models will be assessed using the baseline data to predict binary response data. Odds ratios and 95% confidence intervals will be reported. Will also summarize the data using descriptive statistics and graphical methods. |
Up to 2 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Ari J Rosenberg, Alliance for Clinical Trials in Oncology
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Stomatognatische ziekten
- Neoplasmata per site
- Neoplasmata
- Neoplasmata per histologisch type
- Hoofd- en nekneoplasmata
- Neoplasmata, glandulair en epitheel
- Carcinoom
- KNO-ziekten
- Faryngeale neoplasmata
- Otorinolaryngologische neoplasmata
- Nasofaryngeale ziekten
- Faryngeale ziekten
- Nasofaryngeale neoplasmata
- Nasofarynxcarcinoom
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Onderzoekstechnieken
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Biologische factoren
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Chemie -technieken, analytisch
- Spectrumanalyse
- Receptoren, celoppervlak
- Membraaneiwitten
- Antigenen
- Antigenen, oppervlak
- Biomarkers
- Receptoren, immunologisch
- Antigenen, differentiatie, T-lymfocyt
- Antigenen, differentiatie
- Immuun checkpoint -eiwitten
- Costimulatoire en remmende T-celreceptoren
- Nivolumab
- Ipilimumab
- Exemplaarbehandeling
- Magnetische resonantiespectroscopie
- cabozantinib
- CTLA-4 antigeen
Andere studie-ID-nummers
- NCI-2023-04469
- U10CA180821 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2023-04469 (Register-ID: CTRP (Clinical Trial Reporting Program))
- A092105 (Andere identificatie: CTEP)
- A092105 (Andere identificatie: Alliance for Clinical Trials in Oncology)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .